
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is projected to experience robust earnings growth, with GAAP earnings expected to reach $4.73 per diluted share in 2025 and increase further to $5.17 per diluted share in 2026, reflecting strong performance in the Human Nutrition and Health segment. The company reported $255.5 million in top-line revenue for the second quarter of 2025, surpassing estimates and demonstrating a slight improvement from both the previous quarter and the same period last year. Additionally, Balchem's financial outlook is reinforced by improving gross and net margins, potential for a debt-free status by the end of next year, and opportunities for accretive mergers and acquisitions due to its strong balance sheet.
Bears say
Balchem Corp has experienced a decline in its price-to-earnings (P/E) multiple from 39.6x to 37.9x, indicating a modest increase in its price target despite underlying revenue and earnings trends weakening within its peer group. The company faces several risks, including slower growth in its core businesses, inflationary pressures affecting its operations, and potential disruptions from regional conflicts, particularly impacting its European operations. Additionally, the Animal Nutrition and Health segment reported sales of $56.4 million, below the estimate of $60 million, further highlighting challenges in achieving revenue targets across its various segments.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares